NASDAQ:XTLB

XTL Biopharmaceuticals (XTLB) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$2.41
$2.49
50-Day Range
$3.43
$5.20
52-Week Range
$1.73
$6.69
Volume
5,253 shs
Average Volume
101,220 shs
Market Capitalization
$13.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.

XTLB Stock News Headlines

XTL Biopharmaceuticals Ltd. ADR
How a $0.25 cent option contract makes my top traders feel
If you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…
Dow Surges 350 Points; Fed Holds Rates Steady
Crude Oil Surges 2%; Signet Jewelers Shares Spike Higher
XTL To Aquire The Social Proxy
XTL Biopharmaceuticals Ltd ADR (XTLB)
How a $0.25 cent option contract makes my top traders feel
If you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…
XTL Biopharmaceuticals Ltd (H2K2.MU)
XTLB XTL Biopharmaceuticals Ltd.
X T L Biopharmaceuticals Ltd
LIFE, TBLT and XTLB among pre market gainers
XTL Biopharmaceuticals Ltd. (XTLB)
See More Headlines
Receive XTLB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for XTL Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/28/2024
Next Earnings (Estimated)
5/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:XTLB
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-1,350,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.73 per share

Miscellaneous

Free Float
3,869,000
Market Cap
$13.20 million
Optionable
Not Optionable
Beta
1.21
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Shlomo Spokone Shalev
    Chief Executive Officer & Executive Director
  • Itay Weinstein
    Chief Financial Officer
  • Daphna Paran
    Medical Director

XTLB Stock Analysis - Frequently Asked Questions

Are investors shorting XTL Biopharmaceuticals?

XTL Biopharmaceuticals saw a decrease in short interest in the month of April. As of April 15th, there was short interest totaling 60,200 shares, a decrease of 86.2% from the March 31st total of 437,200 shares. Based on an average daily volume of 726,100 shares, the short-interest ratio is presently 0.1 days.
View XTL Biopharmaceuticals' Short Interest
.

When is XTL Biopharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024.
View our XTLB earnings forecast
.

When did XTL Biopharmaceuticals' stock split?

XTL Biopharmaceuticals's stock reverse split on the morning of Friday, February 10th 2017. The 1-5 reverse split was announced on Wednesday, January 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

What other stocks do shareholders of XTL Biopharmaceuticals own?
This page (NASDAQ:XTLB) was last updated on 4/28/2024 by MarketBeat.com Staff

From Our Partners